Novo Nordisk Gets US Approval for Wegovy Obesity Pill

Good morning. Novo Nordisk gets a head start over rival Eli Lilly. The year-end markets rally continues. Hear what some of Britain’s bosses have to say about 2026. Listen to...

By Chian-Wei Teo · Bloomberg

Good morning. Novo Nordisk gets a head start over rival Eli Lilly. The year-end markets rally continues. Hear what some of Britain’s bosses have to say about 2026. Listen to the day’s top stories.